Gut Feelings Psychiatry has announced the inclusion of psychedelics in its treatment options, specifically targeting individuals suffering from severe or treatment-resistant depression. This innovative approach utilizes ketamine in various forms, such as intramuscular, intravenous, and intranasal, which has demonstrated potential in alleviating depression symptoms. Although ketamine's use for depression is considered off-label, the clinic is an approved Risk Evaluation and Mitigation Strategy (REMS) site for intranasal esketamine, known as Spravato, which has FDA approval and may be covered by insurance.
The clinic's decision to incorporate psychedelics into its treatment repertoire underscores a growing recognition of their therapeutic potential in mental health care. By offering these treatments alongside traditional services like medication management, weight loss programs, and chronic gut health attention, Gut Feelings Psychiatry aims to adopt a more holistic approach to patient wellness. Additionally, the clinic extends its expertise beyond clinical services to include business advising and public speaking, further emphasizing its commitment to comprehensive health and wellness solutions.
This expansion of treatment options is particularly significant for patients in CA, NY, TX, FL, CO, IL, NC, and PA, where Gut Feelings Psychiatry offers virtual services, as well as in-person consultations in Oakland, Berkeley, San Francisco, and Walnut Creek. The inclusion of psychedelics in mental health treatment not only represents a pivotal shift in therapeutic approaches but also highlights the clinic's dedication to exploring innovative solutions for complex health challenges.
